PPT-A Multicenter Randomized Trial Evaluating Clinically Significant Bleeding with Low-Dose

Magnus Ohman MB on behalf of the GEMINIACS1 Investigators Committees and D isclosures Academic Executive Committee E Magnus Ohman MB Cochair C Michael Gibson MS MD Cochair Matthew T Roe MD MHS. Alexander T Cohen . On behalf of the MAGELLAN Steering Committee and Investigators. Potential conflicts. Dr AT Cohen is a medical consultant for and has received honoraria, consultancy and clinical trial funding from many pharmaceutical companies, including: . Allyson Sarigianis, Pharm.D.. October 19, 2013. Objectives. Review current practice recommendations for prevention of stroke/systemic embolism in atrial fibrillation. Compare and contrast pharmacology between warfarin and target specific oral anticoagulants (TSOACs). G. . Turpie. Professor Emeritus of Medicine. McMaster University. Hamilton ON. Canada. Future Challenges. Disclosures for Dr A.G.G. Turpie. Research Support. None. Employee. None. Consultant and/or Honoraria. Magnus Ohman MB, on behalf of the GEMINI-ACS-1 Investigators. Committees and . D. isclosures. Academic Executive Committee. E. Magnus Ohman, MB - Co-chair. C. Michael Gibson, MS, MD - Co-chair. Matthew T. Roe, MD, MHS. Mortality Risks . in . Elderly Medicare Beneficiaries . Treated . with Dabigatran . or Rivaroxaban . for . Nonvalvular. Atrial Fibrillation. To compare risks of thromboembolic stroke, intracranial hemorrhage, major . Babak Moini, MD. Veterans Affairs Hospital. Noon Lecture . S. eries. Acknowledgment: . Some of the slides were borrowed from Amanda Miller Phar.D. . Case1. 68 male with . hx. of DM, CHF and prior ischemic CVA admitted for new . Rivaroxaban Plus Aspirin in Patients With and Without Heart Failure and Chronic Coronary or Peripheral Artery Disease: The COMPASS Trial Kelley Branch, MD, MSc, on behalf of the COMPASS Steering Committee and Investigators Dr. Phil Wells on behalf of the EINSTEIN CHOICE Steering Committee and Investigators Weitz JI et al. N Engl J Med 2017 ( In Press) Rivaroxaban or Aspirin for Extended Treatment of Venous  Thromboembolism Bleeding and cancer risk in patients with vascular disease COMPASS Steering Committee and Investigators Background Community studies have shown that gastrointestinal (GI) and genitourinary (GU) bleeding may be the first sign of underlying cancer Intravenous Access Based on Comfort Cost and Complications Jovie P Velasco BSN RN CCRN Jenifer Beaty BSN RN Lori Ann Engelke RN CRNI Mona Guilfoil RN CRNI OCN Barbara Major RN PCCNTanja Gross BSN RN P rivaroxaban. group vs. 1.02% of the vitamin K antagonist group (p = . NS). Major bleeding: 0.61% of the . rivaroxaban. group vs. 0.80% of the placebo group (p = . NS). Trial design:. . Participants with . Kourosh. . Sadeghi. Tehran University of medical sciences. New Oral Anticoagulants (NOACs). Available in Iran. NOACs. Clinical Trials. RE-LY Study. 951 . clinical . centers in . 44 . countries, . Non-inferiority trial, 18,113 patients, fixed doses of dabigatran 110 mg or 150 mg twice daily — or, in an un-blinded fashion, adjusted-dose warfarin. . Natascha Drude, Clarissa França Dias Carneiro, Meggie Danziger, Anja Collazo, Silke Kniffert, Ulrich Dirnagl, . Ulf Tölch . Reproducibility and the challenge of translation . 19.08.2022. 2. weed out false positives. B. rain . I. njury . T. reatment Trial: A Multicenter Phase II Adaptive Clinical Trial. . Gaylan. . Rockswold. , MD, PhD, Principal Investigator. Thomas Bergman, MD, Site Principal Investigator. Overview.